Psoriasis News and Research

Latest Psoriasis News and Research

Diplomat Specialty Pharmacy to help patients obtain financial assistance to purchase life-saving drugs

Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, is on a mission to help patients obtain the financial assistance they need to purchase life-saving drugs for such illnesses as cancer, HIV/AIDS and Hepatitis C, as well as drugs for Multiple Sclerosis, kidney disease and other chronic conditions.

4 Mar 2010

AARDA report examining current state of AD released at the National Autoimmune Diseases Summit

A groundbreaking new report from the American Autoimmune Related Diseases Association, examining the current state of autoimmune disease (AD) and its economic and social impact globally and in the U.S., was released today at the National Autoimmune Diseases Summit: The Global State of Autoimmunity Today, held to kick-off National Autoimmune Disease Awareness Month.

4 Mar 2010

Lotus Pharmaceuticals adds five new prescription drugs to its products

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that it had added five new prescription drugs to its products delivered through its national sales channels.

3 Mar 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

3 Mar 2010

Dead Sea resorts introduce world-renowned treatment for people with dermatological diseases

The Dead Sea is the only place in the world that combines year-round hot weather, an oxygen-enriched atmosphere, therapeutic UVB solar radiation, a mineral-rich salt sea, world famous mineral-rich mud, thermo-mineral hot springs and luxurious spas.

3 Mar 2010

EMA validates Lux Biosciences' voclosporin MAA

Isotechnika Pharma Inc. today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) filed by its partner, Lux Biosciences, Inc., for voclosporin. Following validation of the MAA, the dossier is distributed to members of the Committee for Medicinal Products for Human Use (CHMP) for formal review, which is expected to take one year.

2 Mar 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

Welichem commences enrollment in WBI-1001 Phase IIa clinical trial for psoriasis

Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

BioTrends' Stelara second wave report finds increase in prescribing among dermatologists

BioTrends published the second wave of LaunchTrends®: Stelara, highlighting dermatology market trends at three months post launch. The report is based on 76 survey responses and 20 qualitative phone interviews with U.S. dermatologists.

19 Feb 2010

Contrast-enhanced MRI may help physicians differentiate between rheumatoid and psoriatic arthritis

Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate between rheumatoid arthritis and psoriatic arthritis in the hand and wrist enabling more targeted therapies unique to each condition, according to a study in the March issue of the American Journal of Roentgenology. Contrast-enhanced MRI uses contrast media to improve the visibility of internal bodily structures.

19 Feb 2010

Isotechnika Labs amends Isodiagnostika sales agreement with Paladin Labs

Isotechnika Pharma Inc. today announced that its wholly owned subsidiary, Isotechnika Labs, has amended its agreement with Paladin Labs Inc. concerning its remaining stake in the revenue stream from the Isodiagnostika business sold to Paladin on June 18, 2009. Under the agreement, Isotechnika Labs was entitled to receive a revenue stream equivalent to 88 percent of the net profits of Isodiagnostika through to June 18 2016.

18 Feb 2010

Advitech to transfer business operations to subsidiary Botaneco Speciality Ingredients

Advitech Inc. announces today its intention to close its office on boulevard Lebourgneuf in Quebec City. Advitech's business operations will be transferred to its subsidiary in Calgary, Botaneco Speciality Ingredients Inc. ("Botaneco"). Following the merger of Advitech and Botaneco in November 2009, this is a significant step towards integrating and optimizing operations of the combined entity.

18 Feb 2010

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

CalciMedica today announced that the US Patent and Trademark Office has issued to CalciMedica US Patent No. 7,645,588, a composition patent involving STIM1, a key component of the calcium release-activated calcium (CRAC) channel. The patent, entitled "Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use," has a priority date of March 4, 2003 and was issued on January 12, 2010.

17 Feb 2010

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference “Advances in Molecular Mechanisms of Atherosclerosis” being held in Banff, Alberta, Canada. Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.

15 Feb 2010

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)—the leading therapy in the psoriasis drug market in 2008—will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Feb 2010

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces the publication of an article, entitled “A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).

10 Feb 2010

MHI researchers receive $4.8M as grants for genetics and genomic medicine research projects

Two research teams led by Dr. Christine Des Rosiers and Dr. John D. Rioux, both researchers at the Montreal Heart Institute (MHI) and professors at the Universit- de Montr-al, have been awarded grants of $2.5 million and $2.3 million, respectively, to finance research projects on genetics and genomic medicine.

10 Feb 2010

Ligon Discovery, Lycera announce collaboration to identify drug candidates for immune disorders

Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.

10 Feb 2010

Psoriasis News and Research

Latest Psoriasis News and Research

Diplomat Specialty Pharmacy to help patients obtain financial assistance to purchase life-saving drugs

AARDA report examining current state of AD released at the National Autoimmune Diseases Summit

Lotus Pharmaceuticals adds five new prescription drugs to its products

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Dead Sea resorts introduce world-renowned treatment for people with dermatological diseases

EMA validates Lux Biosciences' voclosporin MAA

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Welichem commences enrollment in WBI-1001 Phase IIa clinical trial for psoriasis

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

BioTrends' Stelara second wave report finds increase in prescribing among dermatologists

Contrast-enhanced MRI may help physicians differentiate between rheumatoid and psoriatic arthritis

Isotechnika Labs amends Isodiagnostika sales agreement with Paladin Labs

Advitech to transfer business operations to subsidiary Botaneco Speciality Ingredients

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

MHI researchers receive $4.8M as grants for genetics and genomic medicine research projects

Ligon Discovery, Lycera announce collaboration to identify drug candidates for immune disorders

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Psoriasis News and Research

Latest Psoriasis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in